How effective is ivonib in the treatment of acute myeloid leukemia (AML)?

Ivosidenib is a targeted therapy drug that mainly treats acute myeloid leukemia (AML) by inhibiting the enzyme activity of IDH1 mutations. IDH1 (isocitrate dehydrogenase 1) mutations are common in AML, especially in some patients with poor prognosis. IDH1 mutations can lead to metabolic abnormalities, thereby promoting the proliferation of leukemia cells. By inhibiting IDH1 mutations, ivonib can restore normal metabolic pathways, slow down the proliferation of leukemia cells, and promote the recovery of normal hematopoietic function.

In clinical trials, ivosidenib has proven effective in patients with IDH1 mutation-positive acute myeloid leukemia. Especially in treatment-naïve patients and patients with relapsed/refractory AML who have not received chemotherapy, the application of ivonib has shown significant therapeutic effects. In an important phase III clinical trial, ivosidenib combined with chemotherapy significantly improved the complete response rate (CR) and progression-free survival (PFS) of patients. Compared with traditional treatment methods, ivosidenib provided higher efficacy and longer survival.

The efficacy of ivonib varies among different patients, especially for those patients with positive IDH1 mutations. However, as treatment progresses, some patients may develop drug resistance. This usually manifests as the leukemia progressing or no longer responding to medications. In order to overcome drug resistance, researchers are exploring combination treatment options, combining ivonib with other targeted drugs or chemotherapy drugs, in an attempt to enhance its efficacy and prolong patient survival.
The efficacy of ivonib is not only reflected in the clinical relief effect, but also includes its improvement in quality of life. Compared with traditional chemotherapy methods, ivonib has milder side effects and is better tolerated by patients, especially in long-term treatment. Therefore, it has become an important treatment option in the treatment of acute myeloid leukemia, especially for IDH1 mutation-positive patients.
Side effects of ivonib are generally mild, with the most common side effects including nausea, fatigue, constipation, and abnormal liver function. Most side effects can be alleviated by symptomatic management, and ivonib causes relatively few side effects compared with traditional chemotherapy drugs. However, a small number of patients may experience more serious adverse reactions, such as QT interval prolongation or hepatotoxicity, and therefore require regular monitoring during use. In general, the side effects of ivonib are relatively controllable and well tolerated by patients.
Reference link: https://www.tibsovo.com/